Abstract Murine L1210 leukaemia cells expressing either the reduced folate carrier (RFC) or the membrane folate receptor (MFR) were studied in vitro and in vivo to assess the dynamics of membrane transport of two categories antifolates; folate-based inhibitors of dihydrofolate reductase (methotrexate, edatrexate, aminopterin, PT523, and PT644) and thymidylate synthase (TS) [CB3717, raltitrexed, plevitrexed (BGC9331), pemetrexed and GW1843]. The potency of in situ inhibition of TS was used as an endpoint to analyze the in vitro dynamics of RFC/ MFR-membrane transport of these antifolates. Both for L1210-RFC and L1210-MFR cells, the potency of in situ TS inhibition was closely correlated with increasing aYnities of these transporters for the antifolates (r = 0.64, P < 0.05 and r = ¡0.65, P < 0.05, respectively). Within the group of antifolates for which MFR had a low binding aYnity, those that had the ability to become polyglutamylated, were more potent inhibitors of TS in situ activity than non-polyglutamatable antifolates. In vivo activity of methotrexate, edatrexate, raltitrexed and pemetrexed was assessed in L1210-RFC and L1210-MFR bearing mice that were fed either a standard or a folate-deWcient chow. Dietary folate depletion signiWcantly reduced the MTD for methotrexate (sevenfold), edatrexate (sevenfold), raltitrexed (50-fold) and pemetrexed (150-fold). Based on increased life spans, antitumor eVects of methotrexate and edatrexate were markedly better in L1210-RFC bearing mice on the folate-deWcient chow (ILS: 455 and 544%, respectively) than on standard chow (ILS: 213 and 263%, respectively). No therapeutic eVects of methotrexate and edatrexate were observed for L1210-MFR bearing mice on either chow condition, which may be consistent with the low binding aYnity for MFR. Irrespective of the folate diet status, pemetrexed and raltitrexed were inactive against both L1210-RFC and L1210-MFR bearing mice, which may be due to high circulating plasma thymidine levels. Collectively, this study underscores that modulation of dietary folate status can provide a basis within which the therapeutic eVect of antifolates may be further improved.
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Introduction
Several distinct routes for the uptake of folates and antifolates have been reported. Of these the reduced folate carrier (RFC) and membrane folate receptors (MFR) are thoroughly characterized [4, 14, 24, 25, 31, 52, 71] . The RFC is an integral membrane glycoprotein that generates folate uptake by a carrier-mediated process through a bi-directional anion exchange mechanism [25, 31] . The RFC is characterized by a high aYnity (K m : 1-10 M) for reduced folates and methotrexate (MTX), whereas it has poor aYnity for oxidized folates such as folic acid (K m : 200-400 M). Membrane folate receptors are membrane-associated folate binding proteins that constitute a second group of folate transporters and are characterized by high binding aYnity for folic acid (K d : 0.1-1 nM) and 5-methyltetrahydrofolate (K d : 3 nM), but markedly lower aYnities for other reduced folates and MTX [26, 29, 44, 64] .
Three isoforms of MFR ( , and ) with distinct binding aYnities for folates and antifolates, have been identiWed. MFR-and MFR-are linked to the cell membrane by a glycosylphosphotidylinositol-anchor [65] , whereas MFRis a secretory form and lacks this anchor [44] . Two mechanisms of internalization of folates by MFR have been proposed: classical endocytosis [47] and a process called potocytosis which involves the sequestration of MFRs in speciWc membrane vesicles (caveolae) in which, upon acidiWcation, the (anti) folates dissociate from the receptors and are transported into the cytosol by a putative folate carrier [2] . Although the exact role and the relative importance of the RFC in mediating antifolate antitumor activity in vivo has been fairly well established [5, 29, 31, 50] , the role of MFR is still unclear [12, 67] . However, it may be anticipated that optimal MFR-mediated transport could be revealed under conditions of low extracellular folates when there is less receptor occupancy and competition with circulating reduced folates [15, 61, 68] .
In addition to inXux into cells, the cytotoxic action of MTX and other antifolates is dependent on binding to the intracellular targets dihydrofolate reductase (DHFR) [35] and thymidylate synthase (TS) [40] , polyglutamylation [33, 34] , and the rate of drug eZux via members of the multidrug resistance protein family [3, 18, 63] . TS is a key enzyme in the de novo synthesis of thymidylate necessary for DNA synthesis. It catalyzes the conversion of deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP), for which 5, 10-methylenetetrahydrofolate is the methyl donor. Inhibition of TS results in depletion of dTMP, which can lead to thymineless death due to inhibition of DNA synthesis [1] . Polyglutamylation is the process of elongation of the (anti) folate molecule by the addition of multiple glutamate moieties to the -carboxyl group of the glutamate side chain. This process is catalyzed by folylpolyglutamate synthetase (FPGS) and results in increased retention of (anti) folates within the cell and increased aYnity for some key enzymes [36] .
Aminopterin (AMT) [10, 58] and edatrexate (EDX) [55] are DHFR inhibitors that are better transported via the RFC and better substrates for FPGS than MTX (Table 1) . PT523 and PT644 are novel DHFR inhibitors that exhibit eYcient RFC transport but their hemiphtaloyl-ornithine side chain withholds them from being polyglutamylated [46, 49] . MFR exhibits, relative to folic acid, a low binding aYnity for the group of DHFR inhibitors MTX, EDX and PT523, whereas a relatively high binding aYnity is noted for the group of antifolate TS inhibitors (Table 1) .
In addition to DHFR, other crucial enzymes in folate metabolism, such as TS, have been exploited as targets for the development of novel antifolates [20, 39] . CB3717 was the Wrst folate-based TS inhibitor, which was withdrawn from clinical development because of renal toxicity [19] . In recent years new antifolate-based TS-inhibitors have been approved for clinical use, including raltitrexed (RTX) [9, 53] and pemetrexed (PMX; ALIMTA™) [16] . Other TS inhibitors such as GW1843 (reformulated as a liposomal compound: GS7904L) and BGC9331 (plevitrexed, ZD9331) are currently being evaluated in clinical trials [6, 8, 13, 21] . RTX [23] and GW1843 [13] are more eYciently transported via the RFC and better substrates for FPGS than MTX. BGC9331 is a non-polyglutamatable TS inhibitor that displays eYcient transport both via the RFC and MFR [21] . PMX mainly inhibits TS but polyglutamate metabolites of this drug are also potent inhibitors of DHFR and glycinamide ribonucleotide formyltransferase, a key enzyme in the de novo purine synthesis [56] . Moreover, PMX is a good substrate for FPGS and RFC and has high binding aYnity for MFR [56] .
Previous studies from our laboratory [66, 68] and others [60, 64] have assessed the diVerential role of RFC and MFR in the growth inhibitory eVects of antifolates in terms of aYnity relationships. In this study, we focused on the dynamics of membrane transport of a series of antifolates (MTX, EDX, AMT, PT523, PT644, CB3717, RTX, BGC9331, GW1843 and PMX) via the RFC and/or MFR using the in situ inhibition of TS as an endpoint. These studies should provide insight whether MFR binding aYnity is correlated with the eYcacy of cell entry and capacity to inhibit TS. Model systems used were L1210 murine leukaemia cells expressing RFC as sole folate transport system [17] , and L1210-MFR cells that lack functional RFC activity but harbour high MFR expression [28] . In addition, we extended these studies to an in vivo setting in which the antitumor eVect of two antifolates with a low MFR binding (EDX and MTX) was compared with two antifolates with high MFR binding capacity (RTX and PMX). Since folate levels in mouse plasma may be amply suYcient to saturate MFR [54, 62] , we also performed experiments in mice kept on a folate-depleted diet aiming to achieve a greater percentage of unoccupied receptors that could bind antifolates. Cell lines L1210-RFC cells, a murine leukaemia cell line that expresses wild type RFC, was cultured in RPMI-1640 medium (containing 2.3 M folic acid), supplemented with 10% FCS, 2 mM glutamine, penicillin (100 units/ml), streptomycin (100 g/ml), and 50 M -mercaptoethanol. L1210-MFR cells overexpress MFR but lack functional RFC activity [28, 68] and were grown in folate-free RPMI-1640 medium, supplemented with 10% dialyzed FCS and 2.5 nM L-LV as the sole folate source. The cell lines were maintained at 37°C in a humidiWed atmosphere with 5% CO 2 . The cells had comparable levels of DHFR, TS and FPGS [68] .
Materials and methods
Chemicals
In situ TS inhibition assay
Inhibitory eVects of antifolates on in situ TS activity were determined as described previously [32, 48] . In short, cells were washed and suspended in folate-free RPMI-1640 medium and samples of 2 £ 10 5 cells in a volume of 150 l were exposed to various concentrations of antifolate drugs for 3, 6, 9, 12 or 24 h at 37°C. One hour before the end of the incubation, 10 l [5-
3 H]-2Ј-deoxycytidine was added to the cell suspensions to a Wnal concentration of 1 M (speciWc activity, 0.7 Ci/nmol). 3 H]-AMT (speciWc activity 0.65 Ci/nmol). After 1, 4 and 24 h, cells were washed twice with ice-cold HEPES-buVered saline solution (HBSS) pH 7.4 by centrifugation and the pellet was resuspended in 1 ml HBSS. A sample of 90 l was counted for radioactivity, 10 l was used to determine the number of cells, the remaining suspension was centrifuged and the pellet was kept at ¡20°C until extraction. The extraction of [ 3 H]-MTX and [
3 H]-AMT polyglutamates and HPLC analysis were performed as described previously [7] .
Mice
Female DBA/2 mice (7-10 weeks) were obtained from Harlan (Zeist, The Netherlands) and maintained under standard conditions [62] . Mice were fed either a standard chow (containing 3.65 mg folic acid per 100 kg) or a folate deWcient (0 mg folic acid per 100 kg) chow (Hope Farms, Woerden, The Netherlands), which was given ad libitum. The animals for low folate diet experiments were fed with the folate deWcient chow for at least 2 weeks prior to the onset of experiments. Under these conditions folate levels in tissues and plasma are reduced within 2 weeks to that observed in humans [62] .
To assess the maximum tolerated doses (MTD) of MTX, EDX, RTX and PMX for mice on a standard diet and for mice on a low folate diet, various doses of each drug were tested (3 mice per dose). MTX and EDX were administered on day 0 and day 7; RTX and PMX were injected once daily on day 0-4. All of the drugs were administered intraperitoneally. All animal experiments were approved by the Animal Ethical Committee of the VU University.
Determination of anti-leukaemic activity
Mice were intraperitoneally inoculated with wild type L1210 cells (1 £ 10 6 per mouse) or L1210-MFR cells (2 £ 10 6 ). Since the doubling rate of L1210 cells is approximately 1.5-fold higher than the variants, the number of injected cells was adjusted accordingly. Treatment was started 24 h after inoculation using the established MTD of the drugs. Mice (5 per group) received bolus injections with MTX or EDX on day 0 and day 7, whereas RTX or PMX were injected daily on day 0-4.
Weight and clinical condition were determined daily. Survival was assessed daily for up to 93 days and was counted from the start of injection of the cells. Mice identiWed as moribund (visual inspection and/or >20% weight loss) were sacriWced by cervical dislocation and survival time was considered the number of days alive plus one. The antileukaemic activity of the antifolates was assessed by calculating the percentage of the increase in life span (ILS), i.e., the ratio of the median survival of treated mice over the median survival of the untreated control group £ 100%.
Ex vivo folic acid binding studies
Ascites was collected from sacriWced mice for determination of [ 3 H]-folic acid binding capacity. Ascites L1210-MFR cells were isolated by centrifugation with FicollIsopaque. One part of the cells was washed with HBSS buVer (pH 7.4) and used for measurement of folic acid binding capacity. The other part of the cells was washed twice with folate free RPMI-1640 medium and subsequently resuspended in folate free RPMI-1640 medium supplemented with 10% dialyzed FCS for a period of 24 h. Cells were counted with a haemocytometer and viability was determined by Trypan-blue dye exclusion.
Folic acid binding capacity of isolated L1210-MFR cells was assessed as described previously [26] . In short, one portion of cells (3-5 £ 10 6 cells/ml) was incubated in HBSS pH 7.4 with 100 pmol [ 3 H]-folic acid (speciWc activity 0.5 Ci/mmol) for 10 min at 4°C. Then cells were centrifuged and the cell pellet was analyzed for radioactivity. The total folic acid binding capacity was determined after a 20 min acidic treatment with HBSS buVer (pH 3.5) to remove surface bound folates [29] . After centrifugation, cells were resuspended in HBSS pH 7.4 and incubated with [ 3 H]-folic acid as described above. Another portion of L1210-MFR cells were resuspended in folate-free RPMI-1640 medium and cultured in vitro for 24 h after which folic acid binding capacity was assessed again.
Statistics
For the relation between TS inhibitory potency of the antifolates and growth inhibitory eVect or folate transporter aYnities, the Spearman ranking correlation coeYcient was calculated. P values < 0.05 were considered to be statistically signiWcant.
Results
In situ TS inhibition studies
The inhibitory eVects of 3 h exposure of the antifolate compounds MTX, AMT, EDX, PT523, PT644, CB3717, BGC9331, RTX, GW1843 and PMX on in situ TS activity of L1210-RFC cells and L1210-MFR cells are listed in Table 2 . All drugs, with the exception of CB3717, displayed rapid and potent inhibition of TS activity in the L1210-RFC cells. A signiWcant correlation was observed between the TSI 50 values for this panel of antifolates and their RFC substrate aYnities (r = 0.64; P < 0.05; Fig. 1a) . Furthermore, TSI 50 values for L1210-RFC cells obtained with the 3-h in situ TS inhibition assay revealed a strong correlation (r = 0.69; P < 0.05; Fig. 1b) with the previously published IC 50 values for cell growth inhibition after 72 h drug exposure [68] . For L1210-MFR cells, an inverse relation was found between the increasing MFR antifolates binding aYnities and the 3-h TSI 50 values (r = ¡0.65; P < 0.05; Fig. 1c ). Finally, a strong correlation (r = 0.87, P < 0.01; Fig. 1d ) was observed between the 3-h TSI 50 values and the IC50 values for growth inhibition of L1210-MFR cells after 72-h drug exposure.
In L1210-MFR cells, the TSI 50 value for 3 h exposure to MTX, PT523 and PT644 were more than 300-fold higher compared to the TSI 50 values in L1210-RFC cells (Table 2) , which may be consistent with the low MFR binding aYnity for these compounds (Table 1) . Interestingly, however, MFR also exhibits a poor binding aYnity for AMT and EDX (Table 1) , but these two DHFR inhibitors demonstrated a much more potent TS inhibitory eVect (Table 2) . Within the group of TS inhibitors, PMX, GW1843, BGC9331 and RTX all displayed a good TS inhibitory eVect after 3 h exposure (Table 2) . Supplementation of medium with 200 nM folic acid had a marked (351-fold) protective eVect against TS inhibition by RTX in L1210-MFR cells (Table 2) , consistent with MFR being the dominant transport route for RTX in these cells. Surprisingly, CB3717, for which MFR has a relatively high binding aYnity and RFC a low aYnity (Table 1) , displayed a low potency of TS inhibition after 3 h drug exposure in L1210-MFR cells, being just 2.6-fold lower than for L1210-RFC cells ( Table 2 ). The TS-inhibitory activity of RTX, BGC9331 and PMX in L1210-MFR was comparable with that of L1210-RFC cells (Table 2 ).
Time dependency
Since data presented in Table 2 indicated that TS in situ inhibition for some antifolates in L1210-MFR cells (in contrast to L1210-RFC cells) was not fully displayed after 3 h of exposure, experiments were extended to 24 h drug exposure. The TS inhibitory eVects of the diVerent antifolates in L1210-MFR cells in relation to exposure-time are depicted in Fig. 2a (for DHFR inhibitors) and Fig. 2b (for TS inhibitors). Extension of the exposure time from 3 to 24 h resulted in a 3-log increase of the TS inhibitory eVect of MTX against L1210-MFR cells; in particular, a marked increase in MTX-activity occurred between 6 and 9 h (Fig. 2a) . The non-polyglutamatable DHFR inhibitors PT523 and PT644 gained increasing TS inhibitory activity over 3-12 h exposure after which the eVect levelled oV (Fig. 2a) . CB3717 demonstrated higher TS inhibitory activity than MTX after short-term exposures (·6 h), however, this property was lost beyond 9 h of drug incubation (Fig. 2b) . For comparison, short exposures of L1210-MFR cells to the TS inhibitors RTX and BGC9331 were already suYcient to achieve their maximal TS inhibitory activity.
Accumulation and polyglutamylation of MTX and AMT
In order to establish whether diVerences ( 50 values for AMT as compared to MTX, and with the higher aYnities of AMT to FPGS compared to MTX.
In vivo dose-Wnding studies
The MTD for the four antifolates was determined both in mice on a standard folate diet and mice on a low folate diet.
The latter was done for two reasons. First, plasma folate levels of mice are approximately fourfold higher than in human plasma and may counteract activity of antifolates [62] . When mice were adapted to a folate-restricted diet, plasma levels were more in line with that of human plasma. Secondly, high plasma folate levels in mice may lead to full occupancy of MFR binding sites which requires a greater degree of competition for antifolates to displace natural folates. It is hypothesized that under a folate-restricted diet, MFR occupancy by natural folates will be lower to allow (Table 4) . Even more substantial dose reductions (50-and 150-fold, respectively) were required for RTX and PMX in low folate mice as compared in mice on a standard diet (Table 4) .
Anti-leukaemic eVect
The anti-leukaemic activity of MTX, EDX, RTX and PMX was evaluated in mice (on either a standard or a low folate diet) that were inoculated with L1210-RFC and L1210-MFR cells (Fig. 3) . MTX and EDX displayed a low antileukaemic activity against L1210-RFC bearing mice on standard folate containing chow: ILS 213% and 263%, respectively (Fig. 3a) . Of note, both MTX and EDX showed markedly enhanced anti-leukaemic activity against L1210-RFC cells bearing mice on a folate deWcient diet (Fig. 3b) , represented by an ILS of 455% (1 out of 5 long term survivors) and 545% (2 out of 5 long term survivors), respectively. RTX and PMX were only marginally active against mice bearing L1210-RFC cells (ILS 144 and 138%, respectively) (Fig. 3a) . Regardless of the folate diet status, MTX, EDX, RTX and PMX were not active against mice inoculated with L1210-MFR cells (Fig. 3c, d ).
Ex vivo analysis of folic acid binding capacity
In order to investigate whether mouse peritoneal residence may inXuence MFR expression on L1210-MFR cells, we analyzed total receptor levels and the percentage of unoccupied receptors in these cells immediately after sacriWcing the mice. Furthermore, since receptor levels may also have been transiently down regulated due to internalization, L1210-MFR cells were again transferred into folate-free medium for 24 h to allow recycling of receptors to the cell surface. The total number of folate receptors in L1210-MFR cells harvested from mice on standard chow was approximately half the number found in these cells when cultured in vitro under low folate conditions (Fig. 4) . After in vivo harvesting of L1210-MFR cells, receptors appeared to be 80-90% occupied with circulating reduced folates. Total MFR binding capacity was almost fully recovered to the level of control L1210-MFR cells after ex vivo culture for 24 h in folate-free medium, suggesting that the original 50% reduction in [ 3 H] folic acid binding capacity is due to internalization of receptors. Following treatment of L1210-MFR bearing mice with the diVerent antifolates these parameters were not changed (results not shown). Under low folate diet conditions in the mice total folate receptor-[ 3 H]-FA binding activity of L1210-MFR was reduced by 40% as compared to cells maintained in vitro at low folate conditions. Interestingly, in contrast to cells on a high folate diet, MFR occupancy under low folate restrictions was only 30-40%. After ex vivo culture of these cells in folate-free medium for 24 h restored original total receptor levels which were still occupied with folates for approx. 25%. 
Discussion
With MTX as its main representative, folate antagonists remain to have an established place in the oncologists' chemotherapeutic armature. Nowadays, second and third generations of folate antagonists are available based on the rationale design of compounds that harbour speciWc membrane transport, polyglutamylation and/or enzyme targeting properties [63] . Since inhibition of TS is the resultant of one or more of these parameters, we used the in situ TS inhibition assay as a tool to obtain insight how for new generation of antifolates this is translated into potential therapeutic activity [32, 48] . In addition the data support further clinical development of AMT, one of the Wrst antifolates to enter the clinic, which is currently being reevaluated for its clinical potential [10, 11] . The Wrst new clinical data warrant development of AMT. This good activity is probably related to its better polyglutamylation pattern compared to MTX. The primary models used in this study included L1210 leukaemia cells that expressed either the classical RFC or MFR as the dominant route of (anti) folate cell entry. Previous notions that eYciency of RFC transport is a determining factor in the potency of hydrophilic antifolates [25, 31] , were re-established by revealing good correlations between RFC aYnities for antifolates and both TSI and IC 50 values for cell growth inhibition (Fig. 1) . We report here (Fig. 1 ) that similar types of correlations are observed for hydrophilic antifolate transport mediated via MFR. Nevertheless, results from the TS in situ assay with L1210-MFR cells provided evidence for some intriguing diversities in the cascade of MFR-mediated cell membrane translocation and targeting of TS. First, for several antifolates including MTX, MFR-mediated transport appears slower than RFC transport. However, a eightfold increase in exposure time (from 3 to 24 h) resulted in an up to 3-log (1,000-fold) increase in TS inhibitory eVect, which is in line with earlier studies on the eVect of duration of exposure on MTX 3 H] folic acid binding before (represents empty receptors) and after brief acid washing of the cells to remove occupied folate from the receptor. Further experimental details are described in the "Materials and methods". * Indicates signiWcantly diVerent (P < 0.01) in free receptors and total receptor binding capacity compared to in vitro control cytotoxicity [30] . Second, compounds for which MFR had equally low aYnities could still diVer two orders of magnitude in potential to inhibit TS as was illustrated for AMT in comparison with MTX ( Table 2 ). The marked diVerential potency by AMT is likely to be due to better transport and more eYcient polyglutamylation than for MTX (Table 3) , which allows a better retention and greater inhibitory eVect on TS activity. Third, compounds for which MFR has similar binding aYnities but have the ability to become polyglutamylated showed much more potent TS inhibitory eVects than non-polyglutamatable compounds. This is best illustrated in a comparison of polyglutamatable MTX versus the non-polyglutamatable compounds PT523 and PT644, of which the latter compound even has a 24-fold gain in MFR binding aYnity over PT523. Since both PT523 and PT644 showed excellent TS inhibitory potential for L1210-RFC cells (Table 2 ; Fig. 2a) , this suggest that in L1210-MFR cells polyglutamylation may be a driving force to release antifolates from the receptor after MFR-mediated cell membrane translocation [59] . Fourth, antifolates for which MFR displays a high aYnity may not necessarily confer a potent TS inhibitory eVect. This may apply for CB3717 for which MFR has a binding aYnity even greater than for folic acid (Table 1) [68] , but this did not translate in a potent TS inhibitory eVect (Table 2 ; Fig. 2b) , presumably because the tight binding attenuates the intracellular release of CB3717 from MFR. Remarkably, PMX which has an even higher aYnity to MFR displays a much lower TSI 50 than CB3717. However, PMX is an excellent substrate for FPGS, allowing a rapid polyglutamylation leading to an eVective TS inhibition in line with the above stated role of polyglutamylation. Finally, although this study did not elaborate as much on the exact mechanism of MFR-mediated antifolates uptake in L1210-MFR cells, receptormediated endocytosis [47] or potocytosis [2] . For the potocytosis route some recent studies revealed a possible candidate transporter that may work in tandem with MFR to facilitate cell membrane translocation of antifolates. This transporter is referred to as proton coupled folate transporter (PCFT) [42] , which functions optimally at mildly acidic pH and has a high aYnity for folic acid and also for the antifolates PMX [43] . Since the substrate aYnities of PCFT for many of the antifolates used in the present study are not yet known, it remains to be established whether PCFT may contribute to the uptake, in tandem with MFR or not, for a broad spectrum of antifolates drugs.
The DHFR inhibitors MTX and EDX displayed potential anti-leukaemic activity against L1210-RFC bearing mice. This is in accordance with a study by Sirotnak et al. [57] with L1210-RFC cells in another mouse strain. Our data show that dietary folate depletion could further enhance the anti-leukaemic eVect of both drugs, most likely due to less competition for cellular uptake and polyglutamylation by circulating plasma folates [27] . In contrast to L1210-RFC cells, MTX and EDX did not evoke a substantial antileukaemic eVect against L1210-MFR cells. This observation may be consistent with the low binding aYnity of MFR for these compounds [68] , which entails a relatively low level of receptor binding along with an attenuated capacity to displace natural folates from the receptor. The lack of antileukaemic activity by RTX and PMX relates to a known phenomenon that high plasma thymidine levels in mice serve as a salvage route to abolish any therapeutic eVect [22, 54, 62] . Since this salvage eVect is not aVected by feeding mice a folate-deWcient chow, this also counteracts an anti-leukaemic eVect of RTX or PMX under these conditions. This comes along with the markedly reduced MTD's for these compounds in mice fed with a folate deWcient chow. Consequently, plasma levels of these antifolates may be insuYcient to achieve a critical state of MFR saturation that is required to elicit an anti-leukaemic eVect. In addition, RTX and PMX do not have an anti-purine eVect similar to MTX, which may also account for the inferior eVects of these compounds in our in vivo model.
For several antifolates, in particular PMX, the therapeutic window is inXuenced by the patients' folate status [37, 38, 54, 62, 70] . The present study indicates that dietary folate modulation in mice provides a condition where folate receptors are less occupied by natural folates (Fig. 4) . Consequently, this may allow enhanced binding of antifolates, especially those for which MFR has a binding aYnity close to folic acid. In this context, some recently identiWed novel antifolates structures, i.e., BGC638 [61] and BGC945 [15] , with the property of not being a substrate for RFC but possessing a good binding aYnity for MFR, warrant further evaluation for selective MFR-mediated cell entry. Finally, recent observations that retinoic acid and histone deacetylase inhibitors can provoked a marked induction of MFR expression [41] may further facilitate selective targeting of MFR.
